Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Mdm1 nuclear protein (MDM1) is a microtubule-binding nuclear protein that localizes primarily to the centrioles of dividing cells and differentiating multiciliated cells[1][2][3][4][5]. It acts as a negative regulator of centriole duplication, likely through direct interaction with and stabilization of microtubules. MDM1's repeat motifs contribute to its microtubule-binding ability. Mutations in MDM1, mainly identified in mouse models, lead to age-related retinal degeneration and are associated with various human ocular diseases, emphasizing the protein's key role in cellular homeostasis and retinal integrity. There is no evidence to support MDM1 being a classical drug target, receptor, enzyme, transporter, or transcription factor; instead, it is best classified as a “microtubule-binding protein” with established roles in centriole biology and retinal pathogenesis, but not as a current therapeutic target[1][2][3][4][5].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Mdm1 nuclear protein (MDM1).